Boyds appoints Neil Chakrabarti as Chief Financial Officer

Written by: Editor
Published on: 30 Mar 2021

Neil Chakrabarti - BoydsLeading pharmaceutical and biotech product development consultancy, Boyds has announced the appointment of Neil Chakrabarti as Chief Financial Officer.

The appointment comes as the company reported a record-breaking 25 percent growth in turnover as demand for its specialist services continues to grow.

Neil is an experienced financial leader and has worked with a number of businesses across the sector including biotech start-up Autolus Therapeutics plc, pharma business Vectura Group plc, leading multinational medical device manufacturer Medtronic plc, and private equity backed business Independent Clinical Services.

Commenting on his appointment, Neil says: “I am delighted to be joining Boyds at this exciting time. The company is experiencing significant growth and I am looking forward to bringing measurable value to the team. Working with Alan and the management team I will be contributing to the development of the business strategy, helping to improve processes and develop systems to support the growth and a move to greater efficiencies. Boyds clearly has an enviable reputation in the market and I am looking forward to driving and supporting growth plans as the company expands its market share.”

Alan Boyd, President and CEO, adds: “Over the past 12 months I have been taking time to reflect on the direction Boyds needs to take. I have been working with the management team and the specialist life sciences team at BDO, to take Boyds to the next level in its growth. This has involved looking at our systems and processes, but also assessing the skills needed for the coming years. Neil’s appointment is instrumental in this and I am pleased to welcome him to the team. His expertise, challenge and focus will add value to the business as a whole, whilst helping us to build robust systems and processes which will support activities across the entire business.”

Boyds, which was established 16 years ago by Professor Alan Boyd and supports the development of medicines for patient benefit, has recently announced the launch of its biggest recruitment drive to date, creating up to ten new roles to enhance its expertise, service demand for its services, and expand the business.

The company is also in the process of establishing an office in the US, which it plans to open this year.

Related links